60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given Sell (E+) Rating at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating restated by Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

A number of other equities analysts have also issued reports on SXTP. Wall Street Zen lowered 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Ascendiant Capital Markets increased their price objective on 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the stock a “buy” rating in a report on Monday, June 2nd. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

60 Degrees Pharmaceuticals Trading Up 8.5%

Shares of 60 Degrees Pharmaceuticals stock opened at $1.41 on Friday. The business’s 50 day simple moving average is $1.68 and its 200-day simple moving average is $2.11. The stock has a market capitalization of $5.78 million, a price-to-earnings ratio of -0.03 and a beta of 2.71. 60 Degrees Pharmaceuticals has a twelve month low of $1.22 and a twelve month high of $12.45.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.01). The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.32 million. Sell-side analysts predict that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.